Home LiteratureArticle Details
PMID: 7884929 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Sequence diversity of V1 and V2 domains of gp120 from human immunodeficiency virus type 1: lack of correlation with viral phenotype.

Journal of virology ·Vol. 69 ·No. 4 ·1995-04-00 ·Pages 2708-15

Wang N, Zhu T, Ho DD

Abstract

We analyzed by PCR and direct sequencing 57 viral sequences from 47 individuals infected with human immunodeficiency virus type 1, focussing on the V1 and V2 regions of gp120. There was extensive length polymorphism in the V1 region, which rendered sequence alignment difficult. The V2 hypervariable locus also displayed considerable length variations, whereas flanking regions were relatively conserved. Two-thirds of the amino acid residues in these flanking regions were highly conserved (> 80%), presumably reflecting their critical contribution to V2 structure or function. We also characterized the syncytium-inducing properties of the isolates from which we derived sequence information. There was no correlation between V1 or V2 sequences and the viral phenotype, contrary to a previous report (M. Groenink, R. A. M. Fouchier, S. Broersen, C. H. Baker, M. Koot, A. B. van't Wout, H. G. Huisman, F. Miedema, M. Tersmette, and H. Schuitemaker, Science 260:1513-1516, 1993). The sequence heterogeneity described in this study provides information to suggest that it would be most difficult to exploit the V1 and V2 domains for vaccine development.

MeSH Terms
Amino Acid Sequence Base Sequence Cells, Cultured Consensus Sequence DNA Primers Genetic Variation HIV Envelope Protein gp120/genetics HIV-1/genetics Humans Molecular Sequence Data Phenotype Phylogeny Sequence Homology, Amino Acid
Chemicals
DNA Primers HIV Envelope Protein gp120
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Wang N
Aaron Diamond AIDS Research Center, New York University School of Medicine, New York 10016.
Zhu T
Ho D D
References (52)
52 references, click to expand
  1. Independent variation and positive selection in env V1 and V2 domains within maternal-infant strains of human immunodeficiency virus type 1 in vivo.
    J Virol. 1993 Jul;67(7):3951-60 PMID: 8510212
  2. Relation of phenotype evolution of HIV-1 to envelope V2 configuration.
    Science. 1993 Jun 4;260(5113):1513-6 PMID: 8502996
  3. V3 loop of the human immunodeficiency virus type 1 Env protein: interpreting sequence variability.
    J Virol. 1993 Sep;67(9):5623-34 PMID: 8350415
  4. Genotypic and phenotypic characterization of HIV-1 patients with primary infection.
    Science. 1993 Aug 27;261(5125):1179-81 PMID: 8356453
  5. Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains.
    J Virol. 1993 Oct;67(10):6136-51 PMID: 7690418
  6. Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains.
    J Virol. 1994 Jan;68(1):400-10 PMID: 7504740
  7. Human immunodeficiency virus type 1 envelope glycoprotein is modified by O-linked oligosaccharides.
    J Virol. 1994 Jan;68(1):463-8 PMID: 8254757
  8. Characterization of mutants of human immunodeficiency virus type 1 that have escaped neutralization by a monoclonal antibody to the gp120 V2 loop.
    J Virol. 1994 Feb;68(2):974-8 PMID: 7507188
  9. Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization.
    J Virol. 1994 Apr;68(4):2253-9 PMID: 8139010
  10. Evidence for a functional interaction between the V1/V2 and C4 domains of human immunodeficiency virus type 1 envelope glycoprotein gp120.
    J Virol. 1994 Apr;68(4):2503-12 PMID: 8139032
  11. Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers.
    J Clin Invest. 1994 Jun;93(6):2505-13 PMID: 7515393
  12. Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression.
    J Virol. 1994 Jul;68(7):4400-8 PMID: 7515972
  13. A novel, glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a highly potent, neutralizing chimpanzee monoclonal antibody.
    J Virol. 1994 Jul;68(7):4636-42 PMID: 7515975
  14. Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge.
    J Virol. 1994 Oct;68(10):6578-88 PMID: 7521918
  15. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1.
    J Virol. 1994 Dec;68(12):8312-20 PMID: 7525987
  16. Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies.
    J Virol. 1994 Dec;68(12):8350-64 PMID: 7525988
  17. Evidence for coinfection by multiple strains of human immunodeficiency virus type 1 subtype B in an acute seroconvertor.
    J Virol. 1995 Feb;69(2):1324-7 PMID: 7815515
  18. Biologic features of HIV-1 that correlate with virulence in the host.
    Science. 1988 Apr 1;240(4848):80-2 PMID: 2832945
  19. Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex.
    J Virol. 1988 Jun;62(6):2026-32 PMID: 3130494
  20. Extensive variation of human immunodeficiency virus type-1 in vivo.
    Nature. 1988 Aug 4;334(6181):440-4 PMID: 3405290
  21. Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates.
    J Virol. 1989 May;63(5):2118-25 PMID: 2564898
  22. Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality.
    Lancet. 1989 May 6;1(8645):983-5 PMID: 2565516
  23. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.
    Proc Natl Acad Sci U S A. 1989 Sep;86(17):6768-72 PMID: 2771954
  24. Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations.
    Cell. 1989 Sep 8;58(5):901-10 PMID: 2550139
  25. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells.
    J Biol Chem. 1990 Jun 25;265(18):10373-82 PMID: 2355006
  26. HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain.
    Nature. 1990 Nov 1;348(6296):69-73 PMID: 2172833
  27. The viral envelope gene is involved in macrophage tropism of a human immunodeficiency virus type 1 strain isolated from brain tissue.
    J Virol. 1990 Dec;64(12):6148-53 PMID: 2243391
  28. Phenotypic heterogeneity in a panel of infectious molecular human immunodeficiency virus type 1 clones derived from a single individual.
    J Virol. 1991 Apr;65(4):1968-75 PMID: 2002552
  29. Discontinuous sequence change of human immunodeficiency virus (HIV) type 1 env sequences in plasma viral and lymphocyte-associated proviral populations in vivo: implications for models of HIV pathogenesis.
    J Virol. 1991 Nov;65(11):6266-76 PMID: 1920632
  30. Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody.
    Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):8949-52 PMID: 1717992
  31. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120.
    J Virol. 1992 Feb;66(2):848-56 PMID: 1370558
  32. Human immunodeficiency virus type 1 envelope gene structure and diversity in vivo and after cocultivation in vitro.
    J Virol. 1992 Feb;66(2):875-85 PMID: 1731112
  33. Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection.
    J Infect Dis. 1992 Mar;165(3):427-32 PMID: 1347054
  34. HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay.
    AIDS. 1992 Jan;6(1):49-54 PMID: 1543566
  35. Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo.
    J Virol. 1992 Apr;66(4):2577-82 PMID: 1548783
  36. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule.
    J Virol. 1992 May;66(5):3183-7 PMID: 1560543
  37. Convergent and divergent sequence evolution in the surface envelope glycoprotein of human immunodeficiency virus type 1 within a single infected patient.
    Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):4835-9 PMID: 1594583
  38. Evolution of the V3 envelope domain in proviral sequences and isolates of human immunodeficiency virus type 1 during transition of the viral biological phenotype.
    J Virol. 1992 Jul;66(7):4622-7 PMID: 1602564
  39. An O-linked carbohydrate neutralization epitope of HIV-1 gp 120 is expressed by HIV-1 env gene recombinant vaccinia virus.
    Arch Virol. 1992;126(1-4):11-20 PMID: 1381907
  40. Alterations in potential sites for glycosylation predominate during evolution of the simian immunodeficiency virus envelope gene in macaques.
    J Virol. 1992 Oct;66(10):5937-48 PMID: 1527847
  41. Complex intrapatient sequence variation in the V1 and V2 hypervariable regions of the HIV-1 gp 120 envelope sequence.
    Virology. 1992 Dec;191(2):837-45 PMID: 1448927
  42. Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals.
    J Virol. 1993 Apr;67(4):1772-7 PMID: 8095306
  43. Both the V2 and V3 regions of the human immunodeficiency virus type 1 surface glycoprotein functionally interact with other envelope regions in syncytium formation.
    J Virol. 1993 Jun;67(6):3232-9 PMID: 7684463
  44. A single amino acid substitution in the V1 loop of human immunodeficiency virus type 1 gp120 alters cellular tropism.
    J Virol. 1993 Jun;67(6):3649-52 PMID: 8497073
  45. Genomic diversity of the acquired immune deficiency syndrome virus HTLV-III: different viruses exhibit greatest divergence in their envelope genes.
    Proc Natl Acad Sci U S A. 1985 Jul;82(14):4813-7 PMID: 2991896
  46. Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS.
    Cell. 1986 Jun 6;45(5):637-48 PMID: 2423250
  47. Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS.
    Science. 1986 Jun 20;232(4757):1548-53 PMID: 3012778
  48. Genetic variability of the AIDS virus: nucleotide sequence analysis of two isolates from African patients.
    Cell. 1986 Jul 4;46(1):63-74 PMID: 2424612
  49. Identification of conserved and divergent domains within the envelope gene of the acquired immunodeficiency syndrome retrovirus.
    Proc Natl Acad Sci U S A. 1986 Jul;83(14):5038-42 PMID: 3014529
  50. Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions.
    J Virol. 1987 Feb;61(2):570-8 PMID: 2433466
  51. Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody.
    J Virol. 1993 Jun;67(6):3674-9 PMID: 8497077
  52. Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions.
    J Virol. 1993 Aug;67(8):4557-65 PMID: 8331723
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
DOI
10.1128/JVI.69.4.2708-2715.1995
Published
1995-04-00
Pages
2708-15
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC188961
Subset
IM
Grants
NIAID NIH HHS · AI24030 · United States
NIAID NIH HHS · AI25541 · United States
NIAID NIH HHS · AI27742 · United States
Databases
GENBANK
U19621, U19622, U19623, U19624, U19625, U19626, U19627, U19628, U19629, U19630, U19631, U19632, U19633, U19634, U19635, U19636, U19637, U19638, U19639, U19640, U19641, U19642, U19643, U19644, U19645, U19646, U19647, U19648, U19649, U19650
External Links
PubMed source DOI: 10.1128/JVI.69.4.2708-2715.1995 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2